Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults older than 18 and younger than 50 years,~* with a weight higher than 40 kg~* Positive conventional confirmatory serology for T. cruzi infection from the NAtional Public Health institute (ISPCH), and~* A positive qPCR~* Have normal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) \> 2 times the upper limit of normal (X ULN);~* Women of reproductive age must have a negative serum pregnancy test, must not be breastfeeding, and must consistently use a highly effective contraceptive method throughout the treatment phase~* Ability to comply with all protocol-specified follow-up tests and visits and have a permanent address;~* Signed written informed consent form~Exclusion Criteria:~* Signs and symptoms of the digestive form of Chagas Disease;~* Chronic cardiac Chagas Disease stage II or higher;~* Acute or chronic health conditions such as acute infections, history of HIV infection, diabetes, liver and kidney disease;~* Hypothyroidism~* Family history of muscle disorders~* Pre-existing heart disease unrelated to Chagas disease;~* Formal contraindication to receive nifurtimox or benznidazole,~* Known history of hypersensitivity, allergy or severe adverse reactions to atorvastatin, benznidazole or nifurtimox;~* History of previous treatment for Chagas Disease;~* History of prior treatment with atorvastatin, lovastatin, rosuvastatin, simvastatin or any other statin;~* Any concomitant use of antimicrobial agents;~* History of alcohol or drug abuse;~* Any condition that precludes oral medication;~* Concomitant or intended use of CYP3A4 modifiers;~* Medical history of familial short QT syndrome or concomitant therapy with medications that may shorten the QT interval.~* Abnormal laboratory test values for the following parameters: total white blood cell count, platelet count, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin or creatinine, or a gamma-glutamyl transferase (GGT) \> 2 times the upper limit of normal (X ULN);~* Being pregnant or breastfeeding~* Refusing to use a highly effective contraceptive method during the treatment phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ATORVASTATIN 40 (Type: EXPERIMENTAL): 40 mg Atorvastatin/day for 120 days P.O.
- ATORVASTATIN 80 (Type: EXPERIMENTAL): 80 mg Atorvastatin/day for 120 days P.O.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo/day for 120 days P.O.

Based on this trial design, predict the completion outcome and termination type (if applicable).